Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03336528 · ClinicalTrials.gov registry record · Phase 4
Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 180
- Enrollment target
NCT03336528 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 180 participants.
The verdict
NCT03336528, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if treatment with degludec insulin when compared to glargine U100 insulin will result in similar blood sugar control in patients with diabetes who are admitted to the hospital and then transition to home after discharge from the hospital.
Interventions
- DRUG Degludec
- DRUG Glargine
- DRUG Aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2018-01-02 |
| Est. Completion | 2021-03-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03336528
The ClinicalTrials.gov registry entry for NCT03336528 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Degludec is the first listed.
NCT03336528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03336528 about?
NCT03336528 is a clinical study titled "Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes". The purpose of this study is to find out if treatment with degludec insulin when compared to glargine U100 insulin will result in similar blood sugar control in patients with diabetes who are admitted to the hospital and then transition to home after discharge from the hospital.
What is the current status of trial NCT03336528?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2018-01-02. Estimated completion is 2021-03-01.
What interventions are being tested in trial NCT03336528?
The interventions under investigation include: Degludec (DRUG), Glargine (DRUG), Aspart (DRUG).
Who is sponsoring clinical trial NCT03336528?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.